Compare IPCA Labs with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs LUPIN - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS LUPIN IPCA LABS/
LUPIN
 
P/E (TTM) x 24.2 41.5 58.4% View Chart
P/BV x 8.7 3.8 227.2% View Chart
Dividend Yield % 0.1 0.6 24.6%  

Financials

 IPCA LABS   LUPIN
EQUITY SHARE DATA
    IPCA LABS
Mar-19
LUPIN
Mar-20
IPCA LABS/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,042882 118.1%   
Low Rs590505 116.9%   
Sales per share (Unadj.) Rs298.6339.4 88.0%  
Earnings per share (Unadj.) Rs35.0-5.9 -588.5%  
Cash flow per share (Unadj.) Rs49.415.5 319.6%  
Dividends per share (Unadj.) Rs3.006.00 50.0%  
Dividend yield (eoy) %0.40.9 42.5%  
Book value per share (Unadj.) Rs247.1276.7 89.3%  
Shares outstanding (eoy) m126.35453.00 27.9%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.72.0 133.7%   
Avg P/E ratio x23.3-116.6 -20.0%  
P/CF ratio (eoy) x16.544.8 36.8%  
Price / Book Value ratio x3.32.5 131.8%  
Dividend payout %8.6-100.9 -8.5%   
Avg Mkt Cap Rs m103,108314,201 32.8%   
No. of employees `00013.418.3 73.4%   
Total wages/salary Rs m7,87429,868 26.4%   
Avg. sales/employee Rs Th2,807.08,400.6 33.4%   
Avg. wages/employee Rs Th585.81,632.0 35.9%   
Avg. net profit/employee Rs Th329.0-147.2 -223.5%   
INCOME DATA
Net Sales Rs m37,732153,748 24.5%  
Other income Rs m5774,838 11.9%   
Total revenues Rs m38,309158,585 24.2%   
Gross profit Rs m6,90124,849 27.8%  
Depreciation Rs m1,8249,702 18.8%   
Interest Rs m1893,630 5.2%   
Profit before tax Rs m5,46516,355 33.4%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m1,04211,571 9.0%   
Profit after tax Rs m4,422-2,694 -164.2%  
Gross profit margin %18.316.2 113.2%  
Effective tax rate %19.170.8 27.0%   
Net profit margin %11.7-1.8 -668.9%  
BALANCE SHEET DATA
Current assets Rs m23,778154,132 15.4%   
Current liabilities Rs m10,97592,252 11.9%   
Net working cap to sales %33.940.2 84.3%  
Current ratio x2.21.7 129.7%  
Inventory Days Days10482 126.4%  
Debtors Days Days66129 51.0%  
Net fixed assets Rs m20,36889,082 22.9%   
Share capital Rs m253906 27.9%   
"Free" reserves Rs m30,971124,461 24.9%   
Net worth Rs m31,224125,367 24.9%   
Long term debt Rs m1,40917,933 7.9%   
Total assets Rs m45,507249,839 18.2%  
Interest coverage x30.05.5 544.2%   
Debt to equity ratio x00.1 31.5%  
Sales to assets ratio x0.80.6 134.7%   
Return on assets %10.10.4 2,704.8%  
Return on equity %14.2-2.1 -659.1%  
Return on capital %17.38.7 198.5%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30851,450 33.6%   
Fx outflow Rs m6,26619,470 32.2%   
Net fx Rs m11,04231,980 34.5%   
CASH FLOW
From Operations Rs m4,92314,688 33.5%  
From Investments Rs m-1,56311,070 -14.1%  
From Financial Activity Rs m-1,832-8,906 20.6%  
Net Cashflow Rs m1,52816,853 9.1%  

Share Holding

Indian Promoters % 45.9 46.6 98.5%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.4 11.3 100.9%  
FIIs % 25.3 31.9 79.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.1 172.3%  
Shareholders   36,892 98,259 37.5%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   SANOFI INDIA  ASTRAZENECA PHARMA  DISHMAN PHARMA  CIPLA  JUBILANT PHARMOVA   

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

IPCA LABS Announces Quarterly Results (3QFY21); Net Profit Up 32.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, IPCA LABS has posted a net profit of Rs 3 bn (up 32.2% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Apr 16, 2021 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS